Retracted: Effect of progestins with different glucocorticoid activity on bone metabolism
Authors:
- 10 September 2007
- journal article
- retracted article
- Published by Wiley in Clinical Endocrinology
- Vol. 68 (3) , 423-428
Abstract
Summary: Objective Progestins are commonly prescribed for hormone replacement therapy (HRT) and contraception. However, the effects of progestins on bone metabolism remain unclear and are often controversial.Design and patients This study was conducted to test the hypothesis that progestins with no significant glucocorticoid activity may be a better choice for HRT to achieve increased beneficial effects on bone metabolism than progestins with strong glucocorticoid activity. A total of 104 postmenopausal women aged 50–75 years with osteoporosis were allocated randomly to three groups: (1) conjugated oestrogen plus medroxyprogesterone acetate (HRT‐MPA, with significant glucocorticoid activity); (2) conjugated oestrogen plus norethisterone (HRT‐NET, with no significant glucocorticoid activity); and (3) control (no treatment).Measurements Vertebral X‐rays and bone mineral density (BMD) at distal 1/3 radius were assessed at baseline and every 6 months during the 2‐year study period, along with markers of bone turnover. The occurrence of new nonvertebral fractures was identified by X‐ray.Results After the 2‐year treatment, mean BMD changes relative to baseline in the HRT‐MPA, HRT‐NET and control groups were 1·6%, 2·3% and –1·9%, respectively. In addition, the rate of increase in HRT‐NET was significantly greater than that in HRT‐MPA (P = 0·019). The incidence of new fractures during the 2‐year treatment in the control group was 26% (9/34). HRT‐NET treatment significantly inhibited the occurrence of new fractures (RR 0·14, 95% CI 0·02–0·93, P = 0·04), while HRT‐MPA treatment failed to show a statistically significant reduction (RR 0·41, 95% CI 0·14–1·24, P = 0·11). Both HRT‐MPA and HRT‐NET treatments significantly decreased serum osteocalcin levels by 29·4% and 23·5%, respectively, after 6 months of treatment, with the decrease in HRT‐MPA being significantly greater than that in HRT‐NET (P = 0·042).Conclusions These findings suggest that progestins with no significant glucocorticoid activity may be a better choice for HRT, resulting in increased beneficial effects on bone metabolism compared with progestins with strong glucocorticoid activity.Keywords
This publication has 38 references indexed in Scilit:
- The effects of synthetic 19-norprogestins on osteoblastic cell function are mediated by their non-phenolic reduced metabolitesJournal of Endocrinology, 2007
- Progesterone- and Dexamethasone-Dependent Osteoprogenitors in Bone Cell Populations Derived from Rat Vertebrae Are Different and DistinctEndocrinology, 1999
- Glucocorticoid-Induced Osteoporosis: Both In Vivo and In Vitro Concentrations of Glucocorticoids Higher Than Physiological Levels Attenuate Osteoblast DifferentiationJournal of Bone and Mineral Research, 1998
- A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptivesThe Journal of Pediatrics, 1996
- Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late post‐menopausal womenClinical Endocrinology, 1996
- Nonsteroidal Progesterone Receptor Ligands. 2. High-Affinity Ligands with Selectivity for Bone Cell Progesterone ReceptorsJournal of Medicinal Chemistry, 1995
- Premenopausal bone loss and depot medroxyprogesterone acetate administrationInternational Journal of Gynecology & Obstetrics, 1994
- Vertebral fracture assessment using a semiquantitative techniqueJournal of Bone and Mineral Research, 1993
- Stimulatory effects of estrogen and progesterone on proliferation and differentiation of normal human osteoblast-like cells in vitroBiochemical and Biophysical Research Communications, 1992
- Bone density in women receiving depot medroxyprogesterone acetate for contraception.BMJ, 1991